|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03320 CHINARES PHARMA
Nominal 
5.330 +0.360 (+7.243%) Profitability Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| ROAA (%) | 1.488% | 1.328% | 1.667% | 1.600% | 1.624% |
| ROAE (%) | 8.119% | 7.114% | 8.611% | 7.857% | 7.628% |
| Return on Capital Employed (%) | 2.817% | 2.669% | 3.425% | 3.733% | 3.514% |
Margin Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Gross Profit Margin (%) | 16.510% | 15.791% | 15.667% | 15.409% | 14.941% |
| EBITDA Margin (%) | 6.365% | 6.023% | 5.895% | 5.646% | 5.461% |
| Pre-tax Profit Margin (%) | 4.376% | 4.242% | 4.038% | 3.832% | 3.551% |
| Net Profit Margin (%) | 1.501% | 1.300% | 1.575% | 1.604% | 1.592% |
Liquidity Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Current Ratio (X) | 1.418 X | 1.406 X | 1.330 X | 1.250 X | 1.250 X |
| Quick Ratio (X) | 1.114 X | 1.125 X | 1.093 X | 1.032 X | 1.040 X |
Leverage Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Total Liabilities / Total Assets(%) | 58.904% | 61.946% | 62.323% | 62.624% | 61.787% |
| Total Debt / Total Assets (%) | 25.334% | 26.771% | 25.190% | 21.626% | 22.750% |
| Net Debt / Total Assets (%) | 19.790% | 20.399% | 15.200% | 14.563% | 15.704% |
| Total Debt / Shareholders' Funds (%) | 140.845% | 143.033% | 135.251% | 107.012% | 110.918% |
| Long Term Debt / Shareholders' Funds (%) | 42.944% | 48.984% | 34.677% | 22.527% | 15.914% |
| Net Debt / Shareholders' Funds (%) | 110.025% | 108.988% | 81.616% | 72.061% | 76.566% |
| Net Cash / (Debt) ($) | (56.562B) | (52.580B) | (37.510B) | (31.387B) | (31.914B) |
| Net Cash / (Debt) per share ($) | (9.003) | (8.369) | (5.971) | (4.996) | (5.080) |
| Total Debt / Capital Employed (%) | 50.421% | 54.967% | 55.236% | 49.711% | 52.730% |
| Interest Coverage Ratio (X) | 6.821 X | 5.790 X | 5.140 X | 4.408 X | 4.064 X |
Efficiency Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Inventory Turnover (Day) | 65.132 Day | 57.974 Day | 51.666 Day | 52.472 Day | 49.828 Day |
| Receivables Turnover (Day) | 117.968 Day | 106.171 Day | 95.936 Day | 100.832 Day | 98.255 Day |
| Payables Turnover (Day) | 83.388 Day | 80.068 Day | 76.938 Day | 79.801 Day | 76.462 Day |
| Remarks: | Real time quote last updated: 26/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 4,045,468 |
| %Change | 20.729% |
| EPS / (LPS) | RMB 0.640 |
| NBV Per Share (¥) | RMB 8.183 |